Literature DB >> 24142626

Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas.

Rahul A Parikh1, Leonard J Appleman, Julie E Bauman, Madhav Sankunny, Dale W Lewis, Anda Vlad, Susanne M Gollin.   

Abstract

The ATR-CHEK1 pathway is upregulated and overactivated in Ataxia Telangiectasia (AT) cells, which lack functional ATM protein. Loss of ATM in AT confers radiosensitivity, although ATR-CHEK1 pathway overactivation compensates, leads to prolonged G(2) arrest after treatment with ionizing radiation (IR), and partially reverses the radiosensitivity. We observed similar upregulation of the ATR-CHEK1 pathway in a subset of oral squamous cell carcinoma (OSCC) cell lines with ATM loss. In the present study, we report copy number gain, amplification, or translocation of the ATR gene in 8 of 20 OSCC cell lines by FISH; whereas the CHEK1 gene showed copy number loss in 12 of 20 cell lines by FISH. Quantitative PCR showed overexpression of both ATR and CHEK1 in 7 of 11 representative OSCC cell lines. Inhibition of ATR or CHEK1 with their respective siRNAs resulted in increased sensitivity of OSCC cell lines to IR by the colony survival assay. siRNA-mediated ATR or CHEK1 knockdown led to loss of G(2) cell cycle accumulation and an increased sub-G(0) apoptotic cell population by flow cytometric analysis. In conclusion, the ATR-CHEK1 pathway is upregulated in a subset of OSCC with distal 11q loss and loss of the G(1) phase cell cycle checkpoint. The upregulated ATR-CHEK1 pathway appears to protect OSCC cells from mitotic catastrophe by enhancing the G(2) checkpoint. Knockdown of ATR and/or CHEK1 increases the sensitivity of OSCC cells to IR. These findings suggest that inhibition of the upregulated ATR-CHEK1 pathway may enhance the efficacy of ionizing radiation treatment of OSCC.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24142626      PMCID: PMC5520977          DOI: 10.1002/gcc.22115

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  42 in total

Review 1.  Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors.

Authors:  Håkan Axelson; Erik Fredlund; Marie Ovenberger; Göran Landberg; Sven Påhlman
Journal:  Semin Cell Dev Biol       Date:  2005-04-26       Impact factor: 7.727

2.  The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.

Authors:  Remko Prevo; Emmanouil Fokas; Philip M Reaper; Peter A Charlton; John R Pollard; W Gillies McKenna; Ruth J Muschel; Thomas B Brunner
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

3.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; Wojciech Michowski; Joshua E Elias; Lisa Becks; Frederic Bienvenu; Agnieszka Zagozdzon; Tapasree Goswami; Yaoyu E Wang; Alan B Clark; Thomas A Kunkel; Tanja van Harn; Bing Xia; Mick Correll; John Quackenbush; David M Livingston; Steven P Gygi; Piotr Sicinski
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

4.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.

Authors:  Claus Storgaard Sørensen; Lasse Tengbjerg Hansen; Jaroslaw Dziegielewski; Randi G Syljuåsen; Cecilia Lundin; Jiri Bartek; Thomas Helleday
Journal:  Nat Cell Biol       Date:  2005-01-23       Impact factor: 28.824

5.  Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.

Authors:  Sean Vance; Erqi Liu; Lili Zhao; Joshua D Parsels; Leslie A Parsels; Jeffery L Brown; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

6.  A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs.

Authors:  A Coquelle; F Toledo; S Stern; A Bieth; M Debatisse
Journal:  Mol Cell       Date:  1998-08       Impact factor: 17.970

Review 7.  Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease.

Authors:  S M Gollin
Journal:  Head Neck       Date:  2001-03       Impact factor: 3.147

8.  Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage.

Authors:  Christopher E Helt; William A Cliby; Peter C Keng; Robert A Bambara; Michael A O'Reilly
Journal:  J Biol Chem       Date:  2004-11-08       Impact factor: 5.157

Review 9.  Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications.

Authors:  Christine H Chung; Maura L Gillison
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

10.  ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation.

Authors:  Ester M Hammond; Mary Jo Dorie; Amato J Giaccia
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

View more
  13 in total

Review 1.  Inside the hypoxic tumour: reprogramming of the DDR and radioresistance.

Authors:  Katheryn Begg; Mahvash Tavassoli
Journal:  Cell Death Discov       Date:  2020-08-18

2.  Targeting lung cancer through inhibition of checkpoint kinases.

Authors:  Randi G Syljuåsen; Grete Hasvold; Sissel Hauge; Åslaug Helland
Journal:  Front Genet       Date:  2015-02-27       Impact factor: 4.599

3.  Recurring Amplification at 11q22.1-q22.2 Locus Plays an Important Role in Lymph Node Metastasis and Radioresistance in OSCC.

Authors:  Priyanka G Bhosale; Manishkumar Pandey; Simona Cristea; Mickey Shah; Asawari Patil; Niko Beerenwinkel; Alejandro A Schäffer; Manoj B Mahimkar
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

4.  MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway.

Authors:  Jie Bao; Yan Yu; Jianan Chen; Yuting He; Xiaolong Chen; Zhigang Ren; Chen Xue; Liwen Liu; Qiuyue Hu; Juan Li; Guangying Cui; Ranran Sun
Journal:  Cell Death Dis       Date:  2018-10-12       Impact factor: 8.469

5.  Integrative genomics analysis of hub genes and their relationship with prognosis and signaling pathways in esophageal squamous cell carcinoma.

Authors:  Fang-Fang Chen; Shi-Rong Zhang; Hao Peng; Yun-Zhao Chen; Xiao-Bin Cui
Journal:  Mol Med Rep       Date:  2019-08-23       Impact factor: 2.952

6.  Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.

Authors:  Chia-Yu Yang; Chiao-Rou Liu; Ian Yi-Feng Chang; Chun-Nan OuYang; Chia-Hsun Hsieh; Yen-Lin Huang; Chun-I Wang; Fei-Wen Jan; Wan-Ling Wang; Ting-Lin Tsai; Hsuan Liu; Ching-Ping Tseng; Yu-Sun Chang; Chih-Ching Wu; Kai-Ping Chang
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

Review 7.  Proliferation and Apoptosis Pathways and Factors in Oral Squamous Cell Carcinoma.

Authors:  Steven He; Rajdeep Chakraborty; Shoba Ranganathan
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

8.  Computing interaction probabilities in signaling networks.

Authors:  Haitham Gabr; Juan Carlos Rivera-Mulia; David M Gilbert; Tamer Kahveci
Journal:  EURASIP J Bioinform Syst Biol       Date:  2015-11-11

Review 9.  Inside the hypoxic tumour: reprogramming of the DDR and radioresistance.

Authors:  Katheryn Begg; Mahvash Tavassoli
Journal:  Cell Death Discov       Date:  2020-08-18

10.  A porcine model of phenylketonuria generated by CRISPR/Cas9 genome editing.

Authors:  Erik A Koppes; Bethany K Redel; Marie A Johnson; Kristen J Skvorak; Lina Ghaloul-Gonzalez; Megan E Yates; Dale W Lewis; Susanne M Gollin; Yijen L Wu; Shawn E Christ; Martine Yerle; Angela Leshinski; Lee D Spate; Joshua A Benne; Stephanie L Murphy; Melissa S Samuel; Eric M Walters; Sarah A Hansen; Kevin D Wells; Uta Lichter-Konecki; Robert A Wagner; Joseph T Newsome; Steven F Dobrowolski; Jerry Vockley; Randall S Prather; Robert D Nicholls
Journal:  JCI Insight       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.